Menu
No results found.
Weekly Share Price & Valuation Overview
BAIYUNSHAN PH
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited researches, develops, manufactures, and sells Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials. The company operates through Great Southern TCM, Great Commerce, Great Health, and Other segments. It is also involved in the wholesale, retail, sale, import, and export of Western and Chinese medicines, medical instruments, pharmaceutical products, medical equipment, and healthcare products; and research and development, production, and sale of beverages, food, healthcare products, and other products; and production and sale of pre-packaged food, dairy products, etc., as well as offers herbal tea, tablets, capsules, lozenges, tortoise herb jelly, etc. In addition, the company invests in health industry, such as medical services, health management, health maintenance, elderly care, etc.; and provides leasing and commercial, health, advertising, loading offloading, and warehouse services. It operates through retail chain pharmacy stores and retail stores. The company has operations in the People's Republic of China and internationally. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Market Cap Total equity value of the company (share price × shares outstanding).
- HKD 45.15B
- Enterprise Value Operating value: market cap + total debt − cash.
- HKD 27.65B
- Total Revenue (TTM) Estimated Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- HKD 10.08B
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- HKD 12.01B
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- HKD 3.88B
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- HKD 45.84
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 1.82
- Dividend Yield Annual dividend ÷ share price. Reconciled using dividend per share when available.
- 4.80%
- Shares Outstanding
- 219.90M
- Float Shares
- 876.40M
- Implied Shares Outstanding
- 2.47B
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
9.61%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
38.51%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
119.11%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
3.62%
- ROA Return on assets: net income ÷ total assets.
-
2.60%
- ROE Return on equity: net income ÷ shareholder equity.
-
7.22%
- Revenue Growth Year-over-year revenue growth.
-
-2.10%
- Earnings Growth (YoY) Year-over-year earnings growth.
-
-7.00%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
-7.00%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 1.18
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.37
- Total Cash Cash and equivalents.
- HKD 18.54B
- Total Debt Short + long-term interest-bearing debt.
- HKD 14.52B
- Net Debt Net Cash Total debt − cash (negative = net cash).
- HKD -4.02B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 3.74
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- HKD 2.68B
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- HKD 521.38M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
26.62%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
5.17%
- Cash Conversion (OpCF/EBITDA)
- 0.69
- Total Revenue (TTM) estimated from Revenue per Share × Shares due to feed inconsistency.
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.